Barcode Nanotech
Target-specific nanoparticles for next generation RNA therapies
StartupBarcode Nanotech is a Nazareth-based startup in the Health Tech & Life Sciences sector, established in 2017. Target-specific nanoparticles for next generation RNA therapies. The company has raised a total of $7.6M across 5 funding rounds, currently at the Seed stage. Barcode Nanotech was founded by Ronen Eavri, Avi Schroeder, Annie Sabbah. Key investors include NGT HealthCare II, OurCrowd, NGT3, among 4 total investors. The company has 1-10 employees. Core technologies: Biologicals, Molecules, Artificial Intelligence.
With $7.6M in total funding, Barcode Nanotech is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQNazareth
- DistrictNorth District
- Last RoundUndisclosed
- NGT HealthCare II
- OurCrowd
- NGT3
4 investors total
Ronen EavriCo-founder & CEO
Avi SchroederCo-founder- Annie SabbahCo-founder & CTO
2 articles covered by sources including medtech.pharmaintelligence.informa.com,
www.businesswire.com.
What does Barcode Nanotech do?
Barcode Nanotech is a leading expert in one of the most pressing needs of RNA/DNA therapeutics – precise and safe delivery to target organs and cells. The company develops targeted delivery vehicles for next generation therapeutics. Our proprietary Lipid Nanoparticles (LNPs) enable precise target-site therapeutic activity, while our unique molecular barcoding-platform allows rapid and enhanced delivery optimization. Barcode's delivery vehicles are developed for selective indications such as hard-to-treat-cancers, metabolic diseases, fibrosis and other unmet diseases. The company has signed collaborative agreements with major drug companies for the development of RNA therapeutics. Our Solution: Barcode Nanotech is generating proprietary lipid nanoparticles (LNPs) that are designed to selectively reach target cells and tissues, while protecting the RNA molecules from degradation. Our LNPs are comprised of proprietary ionized lipids and formulations. Our nanoparticles formulations are generated and tested using a unique platform, comprised of the following key elements: (i) An AI-based platform for designing proprietary lipid nanoparticles - for selective delivery of RNA/DNA-therapeutics to target organs and cells (*proprietary ionized lipids + proprietary formulations) (ii) A high-throughput in vivo screening platform that enables rapid simultaneous testing and accurate delivery measurement of tens of particles in a single mouse (iii) LNP optimization platform
How much funding has Barcode Nanotech raised?
Barcode Nanotech has raised $7.6M in total funding across 5 rounds. The company is currently at the Seed stage. Key investors include NGT HealthCare II, OurCrowd, NGT3.
Who founded Barcode Nanotech?
Barcode Nanotech was founded in 2017 by Ronen Eavri (Co-founder & CEO), Avi Schroeder (Co-founder), Annie Sabbah (Co-founder & CTO).
What sector is Barcode Nanotech in?
Barcode Nanotech operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Pharmaceuticals.
Where is Barcode Nanotech located?
Barcode Nanotech is based in Wadi el-Haj Street 13, Nazareth, Israel, North District.